MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Foundation Medicine

< Previous 1 2 3 Next >
News headline image
Foundation Medicine Drives Awareness on the Importance of Quality and Accuracy in Cancer Biomarker Testing
From Foundation Medicine
Via Business Wire
News headline image
U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine and SWOG Clinical Trials Partnerships Announce Strategic Collaboration to Advance Biomarker-Driven Research and Clinical Trials
From Foundation Medicine
Via Business Wire
News headline image
US FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for TALZENNA® (talazoparib) in Combination with XTANDI® (enzalutamide) to Identify Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Launches FoundationOne®MRD, First-of-Its-Kind Molecular Residual Disease Test to Combine Structural Variants and Digital PCR
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine to Launch Advanced Digital Solutions to Support Faster Cancer Treatment Decision Making
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Showcases Innovation at 2026 ASCO® Annual Meeting
From Foundation Medicine
Via Business Wire
News headline image
U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for TEPMETKO® (tepotinib) to Identify Patients with MET Exon 14 Skipping Alterations in Non-Small Cell Lung Cancer
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Launches Whole Genome Sequencing Germline Test for Research Use to Accelerate Biopharmaceutical Research and Therapy Development Beyond Oncology
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Announces Expanded Participation in National Cancer Institute’s ComboMATCH Platform Trials Through Inclusion of Its High-Quality Blood-Based Biomarker Test, FoundationOne®Liquid CDx
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Achieves Historic Milestone of 100 Approved and Active Companion Diagnostic Indications, Solidifying Leadership in Precision Medicine
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine and Manifold Partner to Accelerate Drug Discovery and Development by Bringing AI-Enabled Analytics to FoundationInsights®
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Spotlights Scientific Achievements Across its Portfolio of High-Quality Biomarker Tests at the 2025 European Society for Medical Oncology (ESMO) Congress
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Awards the Improving Diagnostics Education and Awareness (IDEA) Program Grant to My Style Matters and H.Y.P.E. to Empower to Increase Biomarker Testing in Black, Latinx and LGBTQ+ Communities
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Launches Molecular Residual Disease (MRD) Test for Research Use in Early to Late-Stage Cancers Through its FlexOMx™ Lab
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Expands Immunohistochemistry (IHC) Testing Portfolio to Include MET IHC Testing
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine to Present Over 15 Abstracts at the 2025 ASCO® Annual Meeting
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Collaborates with Sumitomo Pharma America to Advance Investigational Treatment for Patients with Acute Leukemia with NPM1 Mutations or KMT2A Rearrangements Using the FoundationOne®Heme Platform
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics
From Foundation Medicine
Via Business Wire
News headline image
U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for OJEMDA™ (tovorafenib) to Treat the Most Common Form of Childhood Brain Tumor in Pediatric Patients
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Awards Grants to Organizations Addressing Disparities in Biomarker Testing for Breast and Prostate Cancer
From Foundation Medicine
Via Business Wire
News headline image
U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® (tepotinib) to Identify Patients with MET Exon 14 Skipping Alterations in Non-Small Cell Lung Cancer
From Foundation Medicine
Via Business Wire
News headline image
U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Awarded Contract by the U.S. Department of Veterans Affairs to Provide Tumor Molecular Profiling to Veterans with Cancer
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Partners with Syndax to Develop a Companion Diagnostic in Hematology and Support Efforts to Pursue Regulatory Approval for an Assay Based on the FoundationOne®Heme Platform
From Foundation Medicine
Via Business Wire
News headline image
U.S. Food and Drug Administration Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Lynparza® (olaparib) in Combination with Abiraterone for Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
From Foundation Medicine
Via Business Wire
News headline image
Foundation Medicine Collaborates With Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine’s RNA Platform
From Foundation Medicine
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story